PBV Stock Chart & Stats
€43.40
€1.00(2.38%)
At close: 4:00 PM EDT
€43.40
€1.00(2.38%)
Day’s Range― - ―
52-Week Range€38.00 - €60.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.02B
Enterprise Value€4.23B
Total Cash (Recent Filing)€89.13M
Total Debt (Recent Filing)€2.06B
Price to Earnings (P/E)13.5
Beta0.32
Next Earnings
Oct 29, 2026EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.59
Shares Outstanding47,374,523
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.67
Price to Book (P/B)1.52
Price to Sales (P/S)2.64
P/FCF Ratio11.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€64.24Price Target Upside48.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)3.96
Revenue Forecast (FY)€1.12B
Bulls Say, Bears Say
Bulls Say
Robust Free Cash Flow GenerationStrong free cash flow provides internal funding for marketing, integration and debt reduction while reducing reliance on external capital. The record first-quarter result and fiscal-year target indicate that cash generation remains a durable support for operations and strategic investment.
Acquisition-led Portfolio ExpansionThe completed acquisitions materially expand Prestige’s revenue base and add exposure to respiratory and therapeutic skincare categories. Their expected contribution, alongside targeted accretive margins, can strengthen scale and earnings capacity over the next several quarters.
Broad Branded Portfolio And Category StrengthStrength across gastrointestinal, skincare and digital channels suggests demand is supported by a diversified branded portfolio rather than one isolated product. This breadth can improve resilience, support retail distribution and provide multiple avenues for sustained organic growth.
Bears Say
Meaningful Leverage And Higher Financing CostsMeaningful leverage and rising interest expense can absorb a larger share of operating cash flow, limiting flexibility for acquisitions, marketing and debt repayment. Although maturities were extended, the elevated financing burden remains a durable constraint on earnings and capital allocation.
Clear Eyes Supply VariabilityThe prolonged Clear Eyes supply disruption can constrain sales availability and require management attention across multiple quarters. Even though the brand is less than 3% of sales, continued output variability may weigh on execution and delay the full realization of portfolio growth.
Gross Margin Pressure From Transportation Costs And MixA 120-basis-point margin decline shows that cost inflation and product mix can pressure profitability even when revenue grows. Sustained transportation costs or unfavorable mix would reduce operating leverage and could limit the cash available for brand investment and deleveraging.
PBV FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was €38.00 and its highest was €60.00 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is €2.02B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Oct 29, 2026 which is in 19 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Aug 06, 2026. The company reported €0.875 earnings per share for the quarter, beating the consensus estimate of €0.798 by €0.077.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare does not currently pay dividends.
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 0.95.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 47,374,523 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of €0.875 in its last earnings report, beating expectations of €0.798. Following the earnings report the stock price went up 4.587%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in DE:PBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€64.24 (48.02% Upside)
€64.24 (48.02% Upside)
Blogger Sentiment
Bullish
DE:PBV Sentiment 60%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.36%
12-Months-Change
Fundamentals
Return on Equity
9.22%
Trailing 12-Months
Asset Growth
33.13%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., along with its various divisions, is involved in the creation, production, promotion, and distribution of non-prescription health and personal care items across both domestic (U.S.) and global markets. The company's business activities are structured into two principal areas: North American Over-the-Counter Healthcare and International Over-the-Counter Healthcare. Their extensive brand catalog features a diverse array of consumer health solutions, including popular choices for pain relief (such as BC/Goody's), infant care (Boudreaux's Butt Paste), sore throat remedies (Chloraseptic), vision care (Clear Eyes, TheraTears), wart treatment (Compound W), dental hygiene (DenTek), earwax removal (Debrox), and motion sickness prevention (Dramamine). The product line further extends to include digestive aids (Fleet, Gaviscon), cough suppressants (Luden's), feminine hygiene items (Monistat, Summer's Eve), treatments for lice and parasites (Nix), nasal washes (Fess), and rehydration therapies (Hydralyte). These offerings reach consumers through a wide range of retail channels, such as large discount retailers, pharmacies, supermarkets, dollar stores, convenience outlets, membership-based clubs, and digital commerce platforms. Founded in 1996 and based in Tarrytown, New York, the organization operated under the name Prestige Brands Holdings, Inc. until its rebranding to Prestige Consumer Healthcare Inc. in August 2018.
PBV Company Deck
PBV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a broadly positive operational and financial start to fiscal '27: reported revenue and adjusted EBITDA grew, record adjusted free cash flow was delivered, and two strategic acquisitions (Breathe Right and LaCorium) were closed and are expected to meaningfully expand revenue and margins. Management acknowledged notable near-term challenges — most prominently Clear Eyes supply variability from Pillar5 integration, YoY gross margin pressure from transportation costs, international distributor timing, and elevated debt/interest costs — but provided specific remediation and integration plans, maintained organic growth guidance (1%–3%) and raised reported guidance driven by acquisitions. Given the strong cash flow, completed integration of Breathe Right, accretive acquisition profile, and maintained outlook despite manageable headwinds, the overall tone and expected trajectory are positive.View all DE:PBV earnings summariesPBV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€64.24
▲(48.02% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
SCYNEXIS
―
Cosmos Holdings
―
Biofrontera
―
Nasus Pharma Ltd.
―
Clinuvel Pharmaceuticals Limited Sponsored ADR
―









